$EXPD

Wolfe Research predicts U.S. imports will shift from East to West Coast ports due to a $3,000 container rate gap, caused by Asian port congestion, blank sailings, and supply chain disruptions. The Panama Canal's transit cuts may further support this shift. Beneficiaries include Union Pacific, J.B. Hunt, CSX, Norfolk Southern, Expeditors International, C.H. Robinson, Matson, and Maersk. J.B. Hunt's Q2 intermodal volumes showed mixed growth.

Global shipping faces declining demand (August US container volumes forecast -4.2% YoY) and elevated freight rates due to geopolitical disruptions. A.P. Moller-Maersk's Q2 freight rates rose 22% YoY, with DBS raising its price target to DKK 17,123. Multiple chokepoints, including the Red Sea and Panama Canal, are increasing costs. Logistics operators like Expeditors International and J.B. Hunt are benefiting, while ZIM Integrated Shipping faces regulatory hurdles.

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.

Expedition Therapeutics (EXPD-101) raised an oversubscribed $115 million Series B led by General Atlantic, with RA Capital and Vivo Capital and other investors. The company dosed the first patient in a global Phase 2 COPD trial of its DPP1 inhibitor EXPD-101. Expedition said Phase 1 showed dose-proportional PK for once-daily oral dosing and no dose-limiting toxicities.

Expeditors International of Washington (EXPD) reported Q2 2026 results with revenue of $3,502.34 million and net income of $266.23 million, and continued share repurchases. The company said it has bought back 121,978,285 shares for about $9.37 billion since 2001, including another $348.45 million in buybacks. Simply Wall St discusses EPS and fair value estimates of about $168 to $178.

Expeditors International of Washington (EXPD) reported Q2 2026 revenue of $3,502.34 million and net income of $266.23 million, with both up year over year, according to the company. The article says EXPD completed a buyback program first announced in 2001 and still had unused capital under a newer 2026 authorization.

Expedition raised $115m in a Series B to advance its COPD drug EXPD-101 through an ongoing Phase II trial (NCT07684820), and to expand its pipeline and discovery platform, according to CEO Yi Larson. EXPD-101 targets neutrophilic inflammation via DPP1 inhibition. The company cited prior Phase I results showing tolerability and once-daily oral dosing support.

Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.

The NYSE pre-market update says the Dow rose above 54,000 for the first time and the S&P 500 closed above 7,700. It notes Expedition Therapeutics secured a $115 million Series B and that first patients were dosed in its Phase 2 trial for EXPD-101 in COPD. It also references Zeta Global’s Q2 beat-and-raise results.

EXPEDITORS INTERNATIONAL OF WASHINGTON INC (EXPD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 EARNINGS RELEASE By: Expeditors International of Washington, Inc. 3545 Factoria Blvd. SE Sterling Plaza 2, 3rd Floor Bellevue, Washington 98006 CONTACTS : Daniel R. Wall David A. Hackett Geoffrey Buscher President and Chief Executive Officer Senior Vice President and